Showing 1894 results
November 2016
-
In The News
Tackling chronic disease with Novartis Access
Chronic diseases like high blood pressure and diabetes impact more than just wealthy nations. Through the Novartis Foundation and Novartis Access, we’re working to address the rising threat of… -
Story Discovery
Women in Science: Hannah Mosca
Oncology Regulatory Affairs Leader Hannah Mosca describes her lifelong interest in science and math, and what it’s like to work at Novartis
-
Press release
Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD)
Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options Results of SUSTAIN will be… -
Press release
Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD
2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro® Breezhaler®, in the treatment of the majority of symptomatic COPD patients Bronchodilation regarded… -
Press release
Innovative study with three treatment switches confirms Sandoz biosimilar etanercept has equivalent efficacy to originator
No clinically meaningful differences between biosimilar etanercept and the originator product in safety and efficacy over 52 weeks[1] Innovative study design demonstrates switching between… -
Press release
Novartis announces AMG 334 significantly reduces monthly migraine days in second pivotal Phase III episodic migraine study
STRIVE, the first six-month placebo-controlled study of AMG 334 (erenumab) in migraine, met the primary endpoint, showing a statistically significant reduction in monthly migraine days versus… -
Press release
Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer
First results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia Sub-group analyses from pivotal MONALEESA-2 trial of… -
Press release
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril[1]… -
Press release
Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis
Priority Review based on data from the largest clinical trials conducted to date in each indication[1],[2] Designation will shorten FDA expected review time to within six months[3]; EMA also… -
Press release
Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain
Cosentyx® data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years[1]* New data show that with Cosentyx the high… -
Press release
Novartis improves ranking in 2016 Access to Medicine Index
Novartis ranks third in 2016 ranking Company tops the industry in access-to-medicine management and capacity building Novartis integrated access strategy addressing all income… -
In The News
The price of drugs should reflect the value they deliver
In Forbes commentary, Novartis CEO says industry should focus on outcomes for patients and healthcare systems.